Stockscreener 앱 받기
5.54
5.30%
-0.31
시장 영업 전:
5.54
전일 마감가:
$5.85
열려 있는:
$5.835
하루 거래량:
1.51M
Relative Volume:
0.81
시가총액:
$417.54M
수익:
$11.40B
순이익/손실:
$-95.73M
주가수익비율:
-2.2612
EPS:
-2.45
순현금흐름:
$-64.37M
1주 성능:
-18.29%
1개월 성능:
-17.56%
6개월 성능:
-1.60%
1년 성능:
-41.81%
1일 변동 폭
$5.475
$5.835
1주일 범위
$5.475
$6.83
52주 변동 폭
$5.0329
$12.22
Mind Medicine Inc Stock (MNMD) Company Profile
명칭
Mind Medicine Inc
전화
212-220-6633
주소
ONE WORLD TRADE CENTER, NEW YORK
MNMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
5.54 | 417.54M | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-28 | 개시 | Evercore ISI | Outperform |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-07-24 | 개시 | ROTH MKM | Buy |
| 2024-05-29 | 개시 | Robert W. Baird | Outperform |
| 2024-04-15 | 개시 | Leerink Partners | Outperform |
| 2023-12-05 | 개시 | Canaccord Genuity | Buy |
| 2022-12-09 | 재개 | ROTH Capital | Buy |
| 2022-11-16 | 개시 | RBC Capital Mkts | Outperform |
| 2022-08-26 | 개시 | Oppenheimer | Outperform |
| 2022-08-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-04 | 개시 | ROTH Capital | Buy |
| 2021-06-28 | 개시 | Maxim Group | Buy |
모두보기
Mind Medicine Inc 주식(MNMD)의 최신 뉴스
Mind Medicine CEO Robert Barrow sells shares worth $142,941 By Investing.com - Investing.com Canada
MindMed Advances Clinical Programs with Strong Financial Backing - TipRanks
Mind Medicine CEO Robert Barrow sells shares worth $142,941 - Investing.com India
MindMed Announces New Employee Inducement Grants - Business Wire
MindMed Strengthens Brain Health Pipeline with Key Technical Talent Acquisition - Stock Titan
Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR
MindMed appoints new Chief Commercial Officer By Investing.com - Investing.com South Africa
MindMed Appoints Matt Wiley as Chief Commercial Officer - Quantisnow
MindMed appoints new Chief Commercial Officer - Investing.com
MindMed Taps Former Jazz Pharma Executive to Lead MM120 Anxiety Drug Launch - Stock Titan
MindMed’s SWOT analysis: psychedelic stock’s journey through mental health market - Investing.com
MindMed at Leerink’s Global Healthcare Conference: Strategic Insights on Psychedelics - Investing.com India
What is HC Wainwright’s Estimate for MNMD FY2029 Earnings? - Defense World
Robert W. Baird Cuts Mind Medicine (MindMed) (NASDAQ:MNMD) Price Target to $16.00 - Defense World
Mind Medicine (MindMed)’s (MNMD) Buy Rating Reiterated at HC Wainwright - Defense World
Mind Medicine’s (MNMD) Recent Achievements Boosting Stock - Markets Insider
Rhumbline Advisers Buys 4,868 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World
Oppenheimer & Co. Inc. Grows Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World
Sanctuary Advisors LLC Lowers Stock Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World
H.C. Wainwright maintains MindMed stock Buy rating, $55 target - Investing.com India
Mind Medicine’s Promising Future: Buy Rating Backed by Strong Phase 3 Prospects and Financial Position - TipRanks
Mind Medicine Inc (MNMD) Q4 2024 Earnings Call Highlights: Strat - GuruFocus.com
Mind Medicine Inc (MNMD) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
MindMed Advances Clinical Trials and Strengthens Financial Position - TipRanks
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months - MSN
MindMed posts strong cash position, progress on LSD treatment - Green Market Report
Earnings call transcript: MindMed misses Q4 2024 EPS forecast, stock slides - Investing.com
Mind Medicine (MindMed) Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Mind Medicine (MindMed) Inc. SEC 10-K Report - TradingView
Mind Medicine reports Q4 EPS (41c), consensus (28c) - TipRanks
MIND MEDICINE Earnings Results: $MNMD Reports Quarterly Earnings - Nasdaq
Mind Medicine (MindMed) Inc. Loss At -$34.74 Mln In Q4 - Nasdaq
MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates - Joplin Globe
MindMed to Present at Leerink’s Global Healthcare Conference 2025 - TipRanks
Can MindMed's Conference Appearance Signal New Brain Health Breakthroughs? - Stock Titan
Learn to Evaluate (MNMD) using the Charts - Stock Traders Daily
Mind Medicine (MindMed) Inc. (MNMD): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
12 Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
Mind Medicine (MindMed) (MNMD) Projected to Post Earnings on Thursday - MarketBeat
Mind Medicine (MindMed) (MNMD) Expected to Announce Quarterly Earnings on Thursday - Defense World
Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Down 5.3%Here's Why - MarketBeat
When the Price of (MNMD) Talks, People Listen - Stock Traders Daily
Can MindMed's 2024 Financial Results Reveal Its Brain Health Pipeline Progress? - StockTitan
Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Down 5.3%Time to Sell? - MarketBeat
Mind Medicine (MindMed) (MNMD) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap UpHere's What Happened - MarketBeat
MNMD Stock Price and Chart — NASDAQ:MNMD - TradingView
Mind Medicine Inc (MNMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.89%
0.13%
자본화:
|
볼륨(24시간):